These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 17468869)

  • 41. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
    Yamasaki S; Heike Y; Mori S; Fukuda T; Maruyama D; Kato R; Usui E; Koido K; Kim S; Tanosaki R; Tobinai K; Teshima T; Takaue Y
    Transpl Infect Dis; 2008 Jul; 10(4):252-9. PubMed ID: 18194371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
    Shimoni A; Hardan I; Shem-Tov N; Rand A; Yerushalmi R; Nagler A
    Leuk Lymphoma; 2007 Dec; 48(12):2352-9. PubMed ID: 18067010
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
    George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
    Bone Marrow Transplant; 2007 Jul; 40(1):13-8. PubMed ID: 17450183
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Wolf D; Wolf AM; Fong D; Rumpold H; Strasak A; Clausen J; Nachbaur D
    Transplantation; 2007 Apr; 83(8):1107-13. PubMed ID: 17452902
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.
    Kim I; Lee KH; Choi Y; Keam B; Koo NH; Yoon SS; Yoo KY; Park S; Kim BK
    J Korean Med Sci; 2007 Apr; 22(2):227-34. PubMed ID: 17449929
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.
    Cho BS; Kim YJ; Cho SG; Kim SY; Eom KS; Kim HJ; Lee S; Min CK; Kim DW; Lee JW; Min WS; Kim CC
    Int J Hematol; 2007 Jun; 85(5):446-55. PubMed ID: 17562624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
    Bonin M; Pursche S; Bergeman T; Leopold T; Illmer T; Ehninger G; Schleyer E; Bornhauser M
    Bone Marrow Transplant; 2007 Feb; 39(4):201-6. PubMed ID: 17211431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
    Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S
    Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
    Buser AS; Stern M; Bucher C; Arber C; Heim D; Halter J; Meyer-Monard S; Stussi G; Lohri A; Ghielmini M; Tichelli A; Passweg JR; Gratwohl A
    Bone Marrow Transplant; 2007 Mar; 39(6):335-40. PubMed ID: 17342158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction.
    Kikuta A; Ito M; Mochizuki K; Akaihata M; Nemoto K; Sano H; Ohto H
    Bone Marrow Transplant; 2006 Nov; 38(10):665-9. PubMed ID: 17013427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
    Gutierrez-Aguirre CH; Cantú-Rodríguez OG; Gonzalez-Llano O; Salazar-Riojas R; Martinez-González O; Jaime-Pérez JC; Morales-Toquero A; Tarín-Arzaga LC; Ruiz-Argüelles GJ; Gómez-Almaguer D
    Hematology; 2007 Jun; 12(3):193-7. PubMed ID: 17558694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.
    Rosser SPA; Brewer A; Gabriel M; Wong M; Chung J; McLachlan AJ; Nath CE; Keogh SJ; Shaw PJ
    Pediatr Transplant; 2024 Jun; 28(4):e14780. PubMed ID: 38766999
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.
    Huisman C; de Weger RA; de Vries L; Tilanus MG; Verdonck LF
    Bone Marrow Transplant; 2007 Mar; 39(5):285-91. PubMed ID: 17262061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.
    Heining C; Spyridonidis A; Bernhardt E; Schulte-Mönting J; Behringer D; Grüllich C; Jakob A; Bertz H; Finke J
    Bone Marrow Transplant; 2007 May; 39(10):613-22. PubMed ID: 17384658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allogeneic stem-cell transplantation with fludarabine and 2-Gy TBI-based conditioning regimen for chronic hematological malignancy: a study of 25 consecutive patients and a literature review.
    Micol JB; Berthon C; Tricot S; Terriou L; Darré S; Cracco P; Boulanger F; Bauters F; Jouet JP; Yakoub-Agha I
    Leuk Lymphoma; 2007 Feb; 48(2):321-9. PubMed ID: 17325892
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen.
    Hansen MD; Filipovich AH; Davies SM; Mehta P; Bleesing J; Jodele S; Hayashi R; Barnes Y; Shenoy S
    Bone Marrow Transplant; 2008 Feb; 41(4):349-53. PubMed ID: 18026148
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Bogunia-Kubik K; Duda D; Suchnicki K; Lange A
    Haematologica; 2006 Dec; 91(12):1628-34. PubMed ID: 17145599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center.
    Uzay A; Gündoğdu Y; Koşan B; Yetiş T; Kartı SS
    Cancer Med; 2024 May; 13(10):e7292. PubMed ID: 38752476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.